|
市場調査レポート
商品コード
1064113
不眠症の世界市場:市場予測、病気の種類別(睡眠の質の低下、睡眠の維持)、投与経路別(オーラルミスト、非経口)、地域別の分析(~2028年)Insomnia Market Forecasts to 2028 - Global Analysis By Type of Diseases (Poor Quality of Sleep, Sleep Maintenance), Route of Administration (Oral Mists, Parenteral) and By Geography |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。 |
不眠症の世界市場:市場予測、病気の種類別(睡眠の質の低下、睡眠の維持)、投与経路別(オーラルミスト、非経口)、地域別の分析(~2028年) |
出版日: 2022年02月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2~3営業日
|
世界の不眠症の市場規模は、2021年は51億2,404万米ドルで、予測期間中に6.2%のCAGRで成長し、2028年には78億744万米ドルに達すると予測されています。
当レポートでは、世界の不眠症市場を調査しており、市場の概要、市場規模や予測、動向、成長要因および阻害要因、治療の種類・病気の種類・投与経路・エンドユーザー・地域別の分析など、包括的な情報を提供しています。
Table17 Global Insomnia Market Outlook, By Capsules (2020-2028) (US $MN)
Note- Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
According to Stratistics MRC, the Global Insomnia Market is accounted for $5124.04 million in 2021 and is expected to reach $7807.44 million by 2028 growing at a CAGR of 6.2% during the forecast period. Insomnia is a common sleep disorder characterized by difficulties in sleep. Insomnia can exist as alone or conjugated with other psychiatric problems. The exact reason for the cause of insomnia is still unknown. It is most common in women and the severity may increase in conditions like postpartum, menopause and pregnancy. Insomnia disorder can be diagnosed in sleep laboratories using various diagnostic devices.
Market Dynamics:
Driver:
Increasing Stress in Work Place
The work conditions are presently a lot of stress for the employees which is further resulting in tension, constant thinking, and loss of sleep. Also, the market is witnessing a huge demand for OTC drugs amongst the different age groups of patients that are suffering from insomnia. Also, owing to the rising incidence of insomnia amongst people due to numerous reasons like tension and stress is likely to act as major drivers for the global growth of the market.
Restraint:
Lack of Clinical Training
Lack of in-depth clinical training in current medical curricula has resulted in delayed or misdiagnosed and improper treatment plans for patients. An increased understanding and screening of insomnia disorder by health care professionals could result in broader public knowledge of insomnia disorder and sleep health.
Opportunity:
Development of New Technologies
The development of new technologies and the introduction of medical devices are anticipated to boost the market growth. The major market players are playing a significant role in the market. For instance, Eisai Co. Ltd received approval from the US Food and Drug Administration (FDA) and the firm launched its in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance in the United States.
Threat:
Strict Condition
As insomnia's drugs can be prescribed by doctors only in special cases and under strict conditions, like morphine. These prescriptions are strictly determined by distribution and storage licenses and laws which act ac a major threat for the growth of the market.
Benzodiazepines segment is expected to be the largest during the forecast period
Benzodiazepines are a type of sedative medication. This means they slow down the body and brain's functions. They can be used to help with anxiety and insomnia (difficult getting to sleep or staying asleep) Benzodiazepines are a group of CNS depressants which induce feelings of calm (anxiolysis), drowsiness and sleep. They act by facilitating the binding of the inhibitory neurotransmitter GABA at various GABA receptors throughout the CNS.
The over-the-counter segment is expected to have the highest CAGR during the forecast period
The over-the-counter sleep aids segment is going to have lucrative growth during the forecast period attributing to the growth of this market includes easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards over-the-counter sleep aid.
Region with highest share:
The North America is projected to hold the highest market share, owing to the growing need for sleep disorder treatment in the US and Canada coupled with the growing prevalence of sleep disorders is driving the market. According to the American Academy of Sleep Medicine 2020, stress can result in adjustment insomnia, which may affect up to 20% of people in the United States each year. Poor sleeping habits in children lead to behavioural insomnia of childhood, affecting 30% of children. Prescription drugs, substance abuse, medical disorders, and mental health conditions cause insomnia, with about 3% of the population having this type of sleep issue. Specific causes include depression, drug withdrawal, obesity, and anaemia.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR. The market expansion in this province can be highly attributed to increased stress level of working population along with shift-work related sleep disorders. Asia-Pacific excluding Japan (APEJ) will also remain a remunerative region for growth of the market Governments in the province are constantly focusing on improving their healthcare system along with the provision of favourable reimbursement policies, which in turn might impact the insomnia market.
Key players in the market:
Some of the key players profiled in the Insomnia Market include Astellas, Biocodex S A, Consumer Healthcare Inc., Dainippon Sumitomo, ECR Pharmaceuticals, Eisai Co., Flynn Pharma, Johnson & Johnson, Meda Consumer Healthcare Inc., Merck & Co. Inc., Neurim, Pernix Therapeutics, Pfizer Inc., Purdue Pharma L.P., Sanofi Pasteur, SkyePharma, Takeda Pharmaceutical Company, Vanda Pharmaceuticals Inc. Zydus Cadila, Minerva Neurosciences Inc.
Key developments:
In in June 2020: Eisai Co. Ltd launched in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. All these factors are projected to increase the growth of the insomnia treatment market in the North Amer.
In July 2019: Zydus Cadila launched Ramelteon tablets, used to treat insomnia, in the US market.
In January 2021: Minerva Neurosciences Inc. and Royalty Pharma plc entered into an agreement under which Royalty Pharma will acquire Minerva's royalty interest in seltorexant. Seltorexant, a selective orexin 2 receptor antagonist, is currently in Phase 3 development for the treatment of major depressive disorder (MDD) with insomnia symptoms.
Type of Therapy's Covered:
Type of Disease's Covered:
Route of Administrations Covered:
Drug Formulations Covered:
Drug Classes Covered:
Applications Covered:
Distribution Channels Covered:
End Users Covered:
Regions Covered:
What our report offers:
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options: